Plain-English translation of NCT06163131 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing endobronchial valves—small one-way devices inserted into your airways to help reduce lung overinflation in people with severe emphysema. Researchers want to understand whether this treatment improves how well your diaphragm (your main breathing muscle) works and whether better diaphragm function leads to improvements in your symptoms, lung function, and ability to be physically active.
Severe emphysema causes the lungs to become overinflated, which pushes down and flattens your diaphragm, making it weaker and less effective at helping you breathe. This study aims to see if the new treatment helps restore normal diaphragm function and whether doctors can predict who will benefit most by checking the muscle immediately after the procedure.
You likely qualify if…
You likely don't qualify if…
You will receive the endobronchial valve procedure as planned. Researchers will use ultrasound to measure how well your diaphragm is moving before the procedure and again shortly after. They will also check your diaphragm function at 90 days after treatment, and track your symptoms, lung function tests, and physical ability over time to see how the treatment affects you.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Denmark
Enrollment target
~35 participants
Started
November 2023
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2023.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.